DPP4 and diabetes mellitus: Thiazolidinediones, glucagon-like peptide-1 agonists, and dipeptidyl peptidase-4 inhibitors alongside combination medical treatment are second-line treatments for DM, meaning advanced DM leads to a higher PMS risk.